Substantial subpial cortical demyelination in progressive multiple sclerosis: have we underestimated the extent of cortical pathology? by Lauren, Griffiths et al.
                                                                                                 www.nnjournal.net
Original Article Open Access
Griffiths et al. Neuroimmunol Neuroinflammation 2020;7:51-67
DOI: 10.20517/2347-8659.2019.21
Neuroimmunology 
and Neuroinflammation
© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, 
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long 
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Substantial subpial cortical demyelination 
in progressive multiple sclerosis: have we 
underestimated the extent of cortical pathology? 
Lauren Griffiths1, Richard Reynolds2, Rhian Evans1, Ryan J. Bevan1, Mark I. Rees1,3, Djordje Gveric2, 
James W. Neal1, Owain W. Howell1,2
1Institute of Life Sciences, Swansea University Medical School, Swansea University, Swansea SA2 8PP, UK.
2Department of Brain Sciences, Faculty of Medicine, Imperial College London, London W5 3EH, UK. 
3Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales NSW 2006, Australia. 
Correspondence to: Dr. Owain W. Howell, Institute of Life Sciences, Swansea University Medical School, Swansea University, 
Singleton Park, Swansea, SA2 8PP, UK. E-mail: o.w.howell@swansea.ac.uk
How to cite this article: Griffiths L, Reynolds R, Evans R, Bevan RJ, Rees MI, Gveric D, Neal JW, Howell OW. Substantial subpial 
cortical demyelination in progressive multiple sclerosis: have we underestimated the extent of cortical pathology? Neuroimmunol 
Neuroinflammation 2020;7:51-67. http://dx.doi.org/10.20517/2347-8659.2019.21
Received: 13 Dec 2019    First Decision: 21 Jan 2020    Revised: 14 Feb 2020    Accepted: 27 Feb 2020    Published: 21 Mar 2020
Science Editor: Roberta Magliozzi    Copy Editor: Jing-Wen Zhang    Production Editor: Jing Yu
Abstract
Aim: Multiple sclerosis (MS) is an inflammatory demyelinating and neurodegenerative disease. Much of the 
complex symptomatology relates to pathology outside the classic white matter plaque, whereby lesions of the 
cortical grey matter, which are difficult to resolve by conventional clinical imaging, are in part predictive of outcome. 
We investigated the extent of grey matter pathology in whole coronal macrosections to reassess the contribution of 
cortical pathology to total demyelinating lesion area in progressive MS. 
Methods: Twenty-two cases of progressive MS were prepared as whole bi-hemispheric macrosections for histology, 
immunostaining and quantitative analysis of lesion number and relative area, leptomeningeal inflammation and 
microglial/macrophage activation. 
Results: Cortical grey matter demyelination was seen in all cases, which was more extensive than in white and deep 
grey matter (hippocampus, thalamus and basal ganglia) and accounted for 0.8%-60.2% of the entire measurable 
cortical ribbon. The pattern of cortical grey matter demyelination was predominantly subpial (mean 90.9%, range 
60%-100%, of total cortical grey matter lesion area) and cases with the largest areas of subpial cortical lesions had 
more and larger deep grey matter lesions, greater numbers of activated microglia/macrophages, both in lesions 
as well as in normal cortical grey matter, together with elevated leptomeningeal inflammation and lymphoid-like 
structures. White matter lesion area was unchanged when compared with the progressive MS cases with little 
subpial cortical demyelination. 
Conclusion: Analysis of whole coronal macrosections reveals cortical demyelination is more extensive than reported 
by conventional histological methods. Cases of progressive MS with substantial subpial cortical demyelination that 
is independent of underlying white matter lesion area support the implications that these lesions may in-part arise 
through different pathogenetic mechanisms. Biomarkers and/or imaging correlates of this subpial pathology are 
required if we are to fully comprehend the clinical disease process. 
Keywords: Leptomeninges, B cell follicle, microglia activation, normal appearing grey matter. 
INTRODUCTION 
Neocortical grey matter demyelination, microglial activation and neurodegeneration, which may in-part be 
driven by inflammation of the overlying leptomeninges, are important pathological processes influencing 
the clinical severity and outcome of multiple sclerosis (MS)[1]. No biomarker or widely available imaging 
technology can fully report the extent of neocortical pathology, which is essential for optimal disease 
management. 
Neocortical and cerebellar cortical pathology is evident from the earliest stages of MS[2-5]. It is a pathological 
hallmark of progressive MS[1,2] and closely associates with clinical severity at all stages[6]. For example, 
the extent of cortical pathology is better at predicting disease outcome than white matter pathology [7]. 
Radiological imaging of grey matter and cortical atrophy are predictive of the conversion to clinically 
definite MS[8-10] or the risk of transitioning to the progressive phase and disability[7,11]. Nevertheless, even 
high fidelity, non-routine, imaging technologies fail to identify lesions of the most superficial cortical 
layers, whilst neuropathological assessment of standard size tissue blocks often underestimates the extent of 
cortical lesions, which can occupy the cortical ribbon over multiple contiguous gyri and sulci[2,12]. 
Lesions of the superficial layers of the neocortex (subpial cortical grey matter lesions) are more numerous 
and sometimes associate topographically with leptomeningeal foci of immune cell aggregates that resemble 
lymphoid-like structures (alternatively termed ectopic B cell follicle structures) seen in other autoimmune, 
chronic inflammatory and infectious diseases[13,14]. Progressive MS cases with leptomeningeal lymphoid-
like structures exhibit a gradient of cortical tissue damage extending away from the pial surface, suggestive 
of factor(s) in the CSF that promote underlying cortical inflammation and injury[15-17], possibly through the 
activation of microglia. The degree of leptomeningeal inflammation correlates with the extent of cortical 
demyelination, neurodegeneration and microglial activation in acute and progressive stages[4,13,18,19], whilst 
white matter lesion area is not changed. These findings suggest that subpial cortical lesions may arise 
through partly independent mechanisms compared with lesions located further from the CSF-filled spaces 
of the pia or ventricular lumen[17]. 
The study of whole bi-hemispheric coronal macrosections, although technically challenging, can reveal 
hitherto undisclosed aspects of MS pathology and better report the extent of global pathology. We analysed 
the distribution and histological characteristics of cortical grey matter, white matter and deep grey matter 
lesions, together with inflammation of the brain and overlying leptomeninges, using whole brain coronal 
sections from 22 cases of progressive MS. We demonstrate the sometimes surprising extent of subpial 
cortical grey matter demyelinating pathology that can be seen and highlight the association between 
subpial and periventricular grey matter lesions, the dissociation between subpial lesion load and white 
matter lesion area, and confirm the close relationship between leptomeningeal inflammation and subpial 
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cortical lesion pathology. This data support efforts to develop brain imaging and biomarker technologies 
for the identification of subpial grey matter lesions to improve disease prediction and monitoring. 
METHODS 
Post-mortem cohort
Formalin fixed, whole brains [n = 22; median age 57 years (range 30-71 years), median disease duration 
21.5 years (2-40 years), female = 17] were available from clinically and neuropathologically validated 
cases of secondary progressive MS (see Table 1 for details). All cases were provided by the UK Multiple 
Sclerosis Society Tissue Bank, Imperial College London, with appropriate research ethics approval (08/
MRE09/31+5). Case selection was based on availability of whole brains with well-preserved leptomeninges 
and accompanying detailed clinical and neuropathology summaries, collected between February 2004 and 
December 2008. Some of these cases have previously been reported[18], but all analysis and data presented 
here are unique to this manuscript. 
Individual progressive MS brains were dissected into 1-cm-thick coronal sections, cut in an anterior 
direction from the mammillary bodies as coronal bi-hemispheric sections (A1, A2 and A3), or posteriorly 
from the mammillary bodies towards the occipital lobe (sections P1, P2 and P3) such that each coronal 
section contained several different cyto-architectonic areas [Figure 1]. For example, coronal section 
A3 includes frontal cortex and poles of the temporal gyrus; coronal section P1 includes motor and 
somatosensory cortex, thalamus and anterior hippocampus; and coronal section P3 includes parietal and 
occipital lobe and occipital horn of the lateral ventricle. Areas of interest for comparison were subdivided 
into: (1) cortical (neocortex); (2) white matter; and (3) hippocampus and deep grey matter [comprising 
caudate, pallidum (interna and externa), putamen, thalamus, hypothalamus and hippocampus and dentate 
gyrus]. 
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Case Sections analysed Sex Age at death (years)
Disease 
duration (years) MS type Cause of death
MS202 A2, P1 F 58 23 SPMS Pulmonary embolism
MS204 A3, P1, P3 M 58 19 SPMS Leukaemia and MS
MS212 A3, P1, P3 F 47 29 SPMS Multiple sclerosis/bronchopneumonia
MS214 P1 F 51 31 SPMS Multiple sclerosis
MS217 A3, P1, P3 F 57 15 SPMS Suicide
MS223 A2 F 45 2 SPMS Multiple sclerosis/bronchopneumonia
MS224 A2, P1, P3 F 59 33 SPMS Multiple sclerosis/bronchopneumonia
MS226 A2, P3 M 64 27 SPMS Multiple sclerosis/pneumonia
MS253 A3, P1, P3 F 37 16 SPMS Multiple sclerosis/pulmonary embolism
MS257 A2, P1, P3 F 49 22 SPMS Aspiration pneumonia
MS258 A2, P1, P3 M 46 20 SPMS Multiple sclerosis
MS278 A3, P1, P3 M 30 21 SPMS Pneumonia
MS293 P1, P3 F 53 18 SPMS Multiple sclerosis
MS295 P1, P3 F 71 15 SPMS Bronchopneumonia
MS323 A4, P1 F 62 31 SPMS Multiple sclerosis/sepsis
MS336 A2, P1, P3 F 57 27 SPMS Multiple sclerosis/resp failure
MS344 P1 F 57 15 SPMS Multiple sclerosis/septicaemia
MS360 A2, P1, P3 M 55 40 SPMS Multiple sclerosis
MS361 P1 F 60 34 SPMS Multiple sclerosis
MS366 P1 F 61 19 SPMS Multiple sclerosis/bronchopneumonia
MS387 P3 F 43 11 SPMS Multiple sclerosis
MS395 A3, P3 M 63 26 SPMS Multiple sclerosis/chest infection
Table 1. Cases and sections used in this study
List of cases, number of coronal planes analysed, disease course and principal cause of death. Sex (Female/Male), age of death and 
disease duration reported in years and disease type (secondary progressive MS). MS: multiple sclerosis; SPMS:  secondary progressive MS
Tissue preparation, staining and characterising demyelinated lesions
Whole coronal tissue sections were processed under vacuum and paraffin wax embedded prior to 
sectioning at 10 µm onto 3-Aminopropyltriethoxysilane-silane (Sigma, UK) coated glass slides using a 
Reicheart-Jung tetrander microtome. Following dewaxing and rehydration, coronal sections from each 
case were stained with luxol fast blue (LFB) and cresyl violet to identify anatomical landmarks (grey and 
white matter) and to facilitate the assessment of total cortical, hippocampal and deep grey matter and white 
matter areas. Subsequent sections were immunostained with anti-proteolipid protein (PLP) and anti-CD68 
primary antisera [Table 2] and revealed by sequential anti-species specific biotinylated secondary and 
avidin-biotin complex (Vector Labs. Ltd.) horse-radish peroxidase conjugated tertiary detection reagent 
with ImmPACT DAB as the reporter chromogen (Vector). All slides were counterstained, dehydrated, 
cleared in xylene and DePeX mounted under glass coverslip (Ted Pella Inc. USA).
Cortical grey matter lesions (GMLs), revealed by anti-PLP immunohistochemistry, were grouped as 
Type I (leukocortical), Type II (intracortical and not contacting the pia or grey/white matter boundary), 
or Type III (extending from the pia, sometimes involving the entire breadth of the cortex and stopping 
at the grey/white matter boundary (Bo Type IV cortical GML[20]). Areas of sparse and patchy anti-PLP 
immunostaining, which reflect incomplete demyelination and/or remyelination, but are notably different to 
the most “normal” grey matter, were labelled as partially de/re-myelinated grey matter[4].
White matter lesions (WMLs) were separately characterised as active inflammatory (confluent in CD68+ 
microglia/macrophages), chronic active (activated microglia/macrophages restricted to the lesion edge 
containing PLP+ and/or LFB+ myelin breakdown products) and chronic inactive lesions (few activated 
microglia/macrophages at the lesion edge without evidence of recent myelin phagocytosis). Additional 
areas of putative remyelinating/shadow plaque (by PLP+ myelin internodes and a classic LFB+ shadow 
appearance) were identified but not quantified. Demyelinating lesions of the hippocampus and deep grey 
matter were identified based on a clear loss of LFB and/or PLP+ immunostain and were characterised as 
active, chronic active or chronic inactive inflammatory demyelinating lesions[21]. 
Figure 1. Study setup and sampling protocol. Whole coronal tissue slabs sectioned along coronal planes A3, P1 and P3 were prepared 
at three levels from immersion fixed brains (A) (created with Biorender.com). Histology and immunohistochemistry (anti-PLP 
immunostaining) revealed tissue anatomy and areas of frank demyelination (B) (MS278 section A3, MS202 section P1 and MS360 
section P3). Stained and mounted tissue sections were digitised and colour masks depicting demyelinating lesions involving the 
neocortical grey matter (red colour mask), deep grey matter and hippocampus (green colour mask) and white matter (blue colour 
mask) were annotated for lesion quantification (C). (B, C) Scale bar = 2 cm. PLP: proteolipid protein 
B
C
A
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Slide digitisation, lesion masks and quantitative analysis
Individual coronal sections were reviewed using an Olympus SZ60 stereo microscope 0.1-10 × magnification) 
and a Zeiss AxioImager Z1 (40-400 × magnification) to identify normal and pathological regions of interest 
in each slide, which were marked on A4-sized print-outs of the same slide captured using a conventional 
document scanner (HP Scanjet 300) at 1200 dpi. 
Quantifying the number and area of cortical, white matter and hippocampus and deep grey matter lesions
The scanned images were used to guide our tracing of white and grey matter areas (from the LFB stained 
section), and areas of cortical, white matter and hippocampus and deep grey matter lesions (PLP+ slide) as 
colour-mask overlays using GNU image manipulation software (GIMP 2.10; see Figure 1). The modified 
high-resolution TIFF images were analysed in ImageJ (https://imagej.net/Fuiji/Downloads) to record the 
total number and area (mm2) of cortical grey matter, white matter and hippocampus and deep grey GML 
area per section, per case. We defined the maximum extent of a Type III lesion for lesion counting as an 
area of complete demyelination that extended over a maximum of two entire sulci and gyri, as some Type 
III lesions extended across three or more gyri or involved the entire superficial cortical grey matter in a 
single hemisphere. Therefore, our Type III lesion count represents individual, small, Type III lesions, as 
well as large subpial lesions, subdivided and quantified as two or more separate lesions. In addition to 
measuring the area of cortical GMLs, the area and relative extent of cortex identified as de/re-myelinated 
cortical grey matter was recorded per section, per case.
To produce illustrative “heat maps” that depict the burden of cortical GMLs in cases defined by lymphoid-
like structure status (absence/presence), we first identified all cortical GMLs in section P1 per case and 
superimposed these lesions as “layer” images on a line-drawn representative whole coronal brain section 
(adapted from plate 34[22]) in GIMP. The final overlaid schema, comprising the “layer” masks of each case 
sampled at the P1 coronal level, revealed the absolute number of lesions by the relative depth of colour at 
that site. 
Determining leptomeningeal inflammation 
A measure of relative leptomeningeal immune cell infiltration per case was reported. Briefly, meningeal 
infiltrates were graded by assessing the extent of Nissl+ counter-stained cellular infiltrates of the intact 
cerebral leptomeninges, with the most notable infiltrate per case, rather than the average extent of 
infiltration, being reported. None to mild leptomeningeal inflammation was rated 0+ (0-5 cells per 100 × 
microscopic field of view; equivalent to 440-µm length of leptomeningeal tissue); diffuse and modest 
rated ++ (equivalent to an infiltrate of 5-50 loosely packed cells); or substantial infiltration rated +++ 
(based on > 50 cells in a tightly packed infiltrate[18]). Bona fide leptomeningeal lymphoid-like structures 
characterised by the presence of an anti-CD35+ reticular network, proliferating B cells (Ki67 antigen+) and 
immunoglobulin+ plasma cells[23] were previously reported in a subset of these cases[18] and the lymphoid-
like structure status (presence or absence of detectable structures) is detailed in is detailed in the results 
section. 
Quantifying activated microglia/macrophages 
The density of CD68+ microglia/macrophages in cortical GML centres, normal appearing cortical grey 
matter or WML centre or normal appearing white matter was quantified from four 40 × images (Zeiss 
Antibody Dilution Target antigen Company and product details
Anti-CD68 1:400 CD68 (macrosialin) Dako; clone kp1
Anti-CD20 1:125 CD20 Dako; clone l26
Anti-PLP 1:1500 Myelin proteolipid protein BioRad; clone plpc1
Table 2. List of primary antibodies used 
Primary antibody, working dilution, principal target and product details. PLP: proteolipid protein  
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AxioImager Z1 and Axiocam Hrc camera) per region of interest captured from cingulate, pre-central gyrus 
(including pre- and post-central superior gyrus), insula cortex in parietal lobe and temporal lobe (medial) 
of each available P1 coronal macrosection, per case. In the absence of a demyelinating lesion, only data 
from the normal appearing tissue were reported for that region, per case. All data were averaged for lesion 
or normal appearing status across the sampled regions and reported as density of CD68+ cells/mm2, for 
comparison between groups. 
Statistical analysis
Group means or medians were compared and plotted using GraphPad Prism 7. All data were assumed to be 
non-normally distributed given the small sample size[24]. The unpaired Kruskal-Wallis with Dunn’s multiple 
comparison post-test was used for three-group comparisons [i.e., when comparing the average area (mm2) 
of cortical and subcortical lesions per section, per case], whilst the Mann-Whitney U test was used when 
comparing two groups (i.e., per cent hippocampus and deep GML in cortical High vs. Low MS). Fischer’s 
exact test compared the actual vs. anticipated proportion of males/females and other clinical variables, such 
as seizures (yes/no) or lymphoid-like structure status (absent/present), between groups. Correlative analysis 
used Spearman’s method and Spearman r and P values were reported. A two-tailed P value of > 0.05 was 
considered significant. 
RESULTS 
We conducted a study of whole coronal sections to better understand the burden of demyelination and 
inflammation in a cohort of 22 cases of secondary progressive MS (SPMS). 
Cortical grey matter is disproportionality demyelinated in progressive MS 
Cortical grey matter (GM), hippocampus and deep GM and WMLs were seen in all 22 cases analysed, 
with lesions noticeable across the coronal planes sampled [Figures 1 and 2A]. The area of demyelination, 
determined from the analysis of LFB and anti-PLP immuno-stained sections, varied considerably amongst 
the MS cohort [Figure 2B]. Quantification of the total area occupied by cortical GMLs, hippocampus and 
deep GML and WMLs revealed the total area of cortical GML (mean 589 mm2, range 25-2563 mm2) to be 
significantly greater than the total hippocampus and deep GML area (mean 81 mm2, range 0-382 mm2) and 
subcortical WML area (mean 203 mm2, range 2-617 mm2; Figure 2B). The relative area of cortical GML (per 
cent GML of total cortical GM) was almost twice that of the relative area of WML of total section WM per 
Figure 2. Demyelinating lesions of the cortical grey matter, deep grey matter and hippocampus and white matter. Anti-PLP 
immunostaining of sections through the rostral-caudal extent of MS212, at coronal levels A3, P1 and P3 (A). Note the widespread 
demyelination of the cortical grey matter (red colour mask). Quantification of the area of demyelinated tissues revealed the total area 
of demyelinated cortical grey matter to exceed that of the total measured area of deep grey matter and white matter (B). Data points 
represent the sum of all demyelinated lesions, per region of interest per case with mean and SD depicted. Groups compared by Kruskal-
Wallis and Dunn’s multiple comparison post-test. Cx: cortical; GML: grey matter lesion; WML: white matter lesion. Scale bar = 1 cm
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case (17.9% ± 2.6% compared with 8.9% ± 1.3% for cortical GML and subcortical WML, respectively, P = 
0.023, non-parametric Mann-Whitney U test). 
Type III cortical grey matter lesions are the most frequent and can affect the entire cortical 
ribbon in a whole coronal section
We noted cases with little and others with expansive areas of cortical GM demyelination in our progressive 
MS cohort [Figure 3A]. We counted the number of separate lesions of the neocortex and white matter and 
showed that the subpial cortical GMLs (Type III and IV lesions; Figure 3B) were more numerous than any 
other cortical grey matter lesion type or white matter lesion (Figure 3C, P < 0.0001). In total, 1884 lesions 
were identified, of which 1363 (72.3%) were subpial (Type III or IV) cortical GMLs.
Subpial cortical GMLs accounted for the largest area of all lesion types measured. We plotted the measured 
area of each lesion type, with the bar height representing the total average area (mm2) of demyelination per 
section, per case, to show the substantial contribution subpial GMLs made to the total lesion area [Figure 3D]. 
Arranging cases according to the total measured area of demyelination [from left (highest), to right (lowest)] 
highlighted that subpial GMLs overwhelmingly accounted for the different total lesion areas between 
cases with relatively high or low total demyelinated lesion area. In cases with relatively lower lesion area 
(cases MS361-MS295), the area of subpial GML as a per cent of total measured lesion area was far less 
than in cases with the higher total lesion area (34.5%, range 8.0%-60.1% vs. 74.3%, range 54.3%-94.9%; P 
< 0.0001, non-parametric Mann-Whitney U test). We compared the relative extent of demyelination in 
Figure 3. Subpial cortical grey matter lesions are the most frequent and occupy the greatest area. Anti-PLP immunostaining of section 
A3 of MS253, MS224 and MS257 revealed subpial (Type III/IV cortical lesions, red mask), intracortical (Type II cortical lesion, orange 
mask) and leukocortical (Type I cortical lesion, yellow mask) lesions. Lesions of the deep grey matter (green) and lesions of white 
matter (blue mask) are also shown (A). Subpial (Type III/IV) lesions were predominant and often spanned multiple gyri (B). Of 1884 
separate lesions, 72.3% were subpial cortical grey matter lesions (C). By plotting the average area of each lesion type (calculated per 
section) and represented per case, we show the heterogeneity of lesion size across our cohort (D), and how subpial cortical lesions 
contribute a large component of the lesion burden, especially in those cases most affected (from MS366 to MS257, for example). Ave: 
average; Cx: cortical; GML: grey matter lesion; PLP: proteolipid protein immunohistochemistry; WML: white matter lesion. (A) Scale bar 
= 1 cm; (B) Scale bar = 1 mm 
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cortical and subcortical tissues and showed that the relative area of total cortical GML was not statistically 
associated with the relative area of WML (r = 0.135, P = 0.549; Table 3). The area of subpial cortical GML 
was significantly associated with the extent of hippocampus and deep GML area (Spearman r = 0.458, P = 
0.036), whilst leukocortical/intracortical GML area was significantly associated with WML area (Spearman 
r = 0.771, P < 0.0001; Table 3). 
Pathological correlates of a high subpial cortical grey matter lesion load
To understand the clinical and pathological associations that might co-exist with subpial cortical GM 
demyelination, we subdivided the cohort based on relative extent of cortical GML area per section, per case 
[Table 4 and Figure 4]. Cases with 15% or greater relative cortical GML of total cortical GM (n = 9 cases in 
total; Figure 4A, which represent cases MS366-MS257 in graph Figure 3D) were designated cortical GML 
High MS (mean cortical GML area 35.6%; range 15.6%-60.2%), whilst the others (n = 13 cases, cortical 
GML less than 12% total cortical GM area) were designated as cortical GML Low MS (mean cortical GML 
area 5.5%; range 0.9%-12.0%). 
The relative area of hippocampus and deep GML was greater in cortical GML High MS [Figure 4B], whilst 
the relative area of WML was not different [Figure 4C]. Cortical GML High MS cases had a greater density 
of CD68+ microglia/macrophages in both GML centre and normal appearing GM regions, in comparison 
to cortical GML Low MS [Figure 4D and G], whilst the density of CD68+ microglia/macrophages was 
only increased in normal appearing WM of cortical GML High cases [Figure 4E and H]. Inflammation of 
the forebrain leptomeninges is associated topographically with subpial cortical demyelination and cases 
with semi-organised lymphoid-like structures are characterised by a more extensive cortical GML load[13]. 
Our designated cortical GML High MS cohort presented with a substantially increased median rating of 
leptomeningeal immune cell infiltrates (P = 0.003, Figure 4F), with seven of nine cases containing at least 
one bona fide lymphoid-like structure [Table 4]. Examples of leptomeningeal infiltrates rated as mild [+; 
Figure 4I and L], modest [++, Figure 4J and M] and substantial [+++, Figure 4K and N] are provided in 
Figure 4. Immune cell aggregates were associated both with areas of partially de/re-myelinated subpial 
cortical GM as well as areas of subpial GM demyelination [Figure 4]. 
Areas of cortical GM defined as partially de/re-myelinated GM ranged from < 1% (0.9%, MS223) to 13.5% 
(MS257) of total cortical GM area per case but were not different between the cortical GML High and Low 
groups (area of partially de/re-myelinated GM = 8.01% vs. 6.13%, for cortical High vs. Low GML cases, 
respectively, P = 0.387). Rudimentary measures of gross brain pathology, such as brain weight at death 
and the measured area of grey and white matter per P1 section (as an indication of regional grey or white 
% Cx GML III/IV % Hippo and deep GML % WML % Total Cx GML
% Cx GML I/II r  = -0.005
P  = 0.982
r  = 0.224
P  = 0.328
r  = 0.771
P  < 0.0001
r  = 0.051
P  = 0.827
% Cx GML III/IV r  = 0.458
P  = 0.037
r  = 0.092
P  = 0.684
r  = 0.988
P  < 0.0001
% Hippo and deep 
GML
r  = 0.169
P  = 0.464
r  = 0.495
P  = 0.023
% WML r  = 0.135
P  = 0.549
Table 3. Correlating cortical, white matter and hippocampus and deep grey matter lesions 
Correlation analysis revealed the relative area of intracortical and leukocortical grey matter lesions (Type I/II cortical lesions) 
associated with the extent of white matter demyelination. Subpial cortical grey matter lesions (Type III/IV) associated with the extent 
of hippocampus and deep grey matter lesion area. Row and column headings refer to: % Cx GML I/II: relative area of intracortical/
leukocortical grey matter lesions; Cx GML III/IV: relative area of subpial cortical grey matter lesions; % Hippo and deep GML: relative 
area of grey matter lesions affecting hippocampus and deep grey matter; % WML: relative area of demyelinated white matter; % Total Cx 
GML: relative area of demyelinated neocortex. Spearman analysis with r  and P  values shown. Significant associations are underlined. Cx: 
cortical; GML: grey matter lesion; WML: white matter lesion
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Figure 4. Defining a cohort of cortical High grey matter lesion MS. Nine progressive MS cases with the greatest relative area of subpial 
cortical demyelination were labelled as Cortical High GML MS and the remaining cases as Cortical Low GML MS (A). Cortical High 
GML MS had a greater area of demyelinated deep grey matter and hippocampus (B), but unchanged white matter lesion areas (C). The 
density of CD68+ microglia/macrophages was increased in both normal appearing GM (NGM) and GML of cortical High GML MS (D) 
but was only different in the underlying normal appearing WM (NWM) (E). Semi-quantitative evaluation of meningeal inflammation 
revealed cortical High GML MS to have increased inflammation of the leptomeninges (F). Examples of CD68+ microglia of a subpial GM 
lesion (G) and CD68+ microglia/macrophages in a white matter lesion (H). Examples of 1-3 rated inflammatory infiltrates (“+” to “+++”) 
of the forebrain meninges [I-N with (L-N) being higher power images of (I-K), respectively]. Please note that infiltrates (I, L, K, N) are 
near partially de/re-myelinated cortex of cortical High GML Case MS257. Cx: cortical; GML: grey matter lesion; NGM: normal appearing 
grey matter; NWM: normal appearing white matter; PLP: proteolipid protein immunohistochemistry; WML: white matter lesion. (G-K) 
Scale bar = 100µm; (L-N) Scale bar = 25 µm
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matter tissue atrophy; data not shown), did not reveal a difference between the cortical GML High and Low 
MS cases [Table 4]. 
Clinical correlations of a high subpial cortical grey matter lesion load
There was no difference in the proportion of males to females or of any reported clinical measure (such as 
the number of relapses in the first two years, the report of seizures or age of death) between cortical GML 
High and Low groups [Table 4]. There was no difference between groups with regards age of disease onset (P 
= 0.11), confirmed age at onset of progressive phase (P = 0.27) or disease duration (P = 0.15). Post-mortem 
delay did not differ between the groups (P = 0.75; Table 4). 
Leptomeningeal inflammation, lymphoid-like structures and cortical demyelination 
We identified four separate “+++” rated foci of substantial leptomeningeal infiltrates in a single P1 
section of Case MS217, which displayed massive cortical, and exclusively subpial, GM demyelination 
(59.6% of cortical GM defined as GML; Figure 5A and B). Progressive MS cases with moderate-to-high 
leptomeningeal inflammation (rated ++/+++ or +++/+++ for immune cell infiltrates) had an increased 
relative cortical GML area compared with those cases with little-to-mild leptomeningeal infiltrates 7.8% 
(range 0.8%-27.7%) vs. 26.2% (range 0.8%-60.2%), P = 0.012, Mann-Whitney U test). The relative area of 
hippocampus and deep GML area (7.4%, range 0%-19.1% vs. 16.4% range 1.4%-69.2%, P = 0.159) and WML 
Case Sex 2yr RR Onset Prog W’chair Died Duration Pm delay Brain weight (g)
Seizures 
(Y/N) LLS
Menin inflam 
(0-3)
Cortical GM High MS
MS202 F 2 35 46 47 58 23 39 1200 N Y 3
MS212 F 1 18 33 35 47 29 66 1314 N Y 3
MS214 F 2 20 31 38 51 31 20 1140 n/d N 2
MS217 F 1 42 49 50 57 15 29 1200 N Y 3
MS257 F 6 27 31 39 49 22 28 1168 Y Y 3
MS278 M 1 9 23 23 30 21 60 1402 Y Y 3
MS323 F 2 31 38 44 62 31 13 1207 Y N 1
MS360 M 1 15 40 51 55 40 18 1063 Y Y 3
MS366 F 3 42 45 53 61 19 14 1090 N Y 3
n  = 9 7F:2M 2 27 38 44 55 23 31.9 1198.2 4Y:4N 7/9 3
Cortical GM Low MS
MS204 M 3 39 44 48 58 19 35 1180 N N 1
MS223 F 4 43 43 45 45 2 72 1004 Y N 1
MS224 F 1 26 35 36 59 33 27 1100 N N 1
MS226 F 5 37 51 58 64 27 27 1300 N N 0
MS253 F 3 21 23 33 37 16 24 1259 N N 2
MS258 M 2 26 35 38 46 20 44 1460 N N 1
MS293 F 2 35 42 43 53 18 44 1250 Y Y 3
MS295 F 5 56 60 62 71 15 42 1166 N N 0
MS336 F 1 30 47 51 57 27 24 1226 N Y 3
MS344 F 6 42 43 47 57 15 14 1062 N N 1
MS361 F 2 26 38 42 60 34 10 956 Y N 1
MS387 F 6 32 35 36 43 11 13 1115 N N 2
MS395 M 1 37 45 52 63 26 4 958 N N 1
n  = 13 10F:3M 3 35 43 45 57 19 24.3 1161.3 3Y:10N 2/13 1
Table 4. Progressive MS cases defined by relative cortical grey matter lesion load 
Associated clinical and pathological data of Cortical High and Cortical Low grey matter lesion MS. Sex (Female/Male), 2yr RR (number 
of relapses in first two years of clinical disease), Onset (retrospectively determined age at first MS symptoms, Prog (age at which disease 
became progressive), Died (age at death), Duration (time from first symptom onset to death), PM delay (post-mortem delay in hours), 
Brain weight (wet brain weight), Seizures (one or more seizures recorded in the clinical notes - Yes or No), LLS [positive (Yes) or negative 
(No)], Menin inflam (relative extent of meningeal inflammation). n/d, not determined, data not available. Text in bold represents median 
or mean (brain weight only) values for each group. LLS: lymphoid-like structure; GM: grey matter; MS: multiple sclerosis; W'chair: age at 
which they required a wheelchair
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lesion area (10.1%, range 0.6%-42.1% vs. 10.0%, range 2.3%-26.5%, P = 0.981) was unchanged between 
leptomeningeal rated moderate-high cases vs. those rated with little-to-mild infiltrates, respectively. The 
relationship between the extent of leptomeningeal inflammation and cortical GML area is presented 
schematically as a heat map of all cortical GMLs observed (in olive green colour) in section P1 of cases 
with mild (rated 0 to +, n = 9) vs. modest/substantial infiltrates (++ to +++, n = 9; Figure 5C). Please note 
that four cases did not have P1 sections available for analysis [Table 1]. 
DISCUSSION
Our quantitative histological analysis of whole coronal macrosections demonstrates cortical grey matter 
demyelination can be the preeminent pathology in some cases of progressive MS and can be used to 
identify a post-mortem cohort with a more severe pathological disease. Subpial cortical grey matter lesions 
associated with the extent of demyelinated deep grey matter and with infiltrates of the leptomeninges but 
importantly did not associate with white matter lesion load. Our study reinforces the concept of a CSF-
derived (outside-in) driver of tissue pathology in SPMS. 
Figure 5. Meningeal inflammation and subpial cortical demyelination. Example infiltrates of the leptomeninges overlying the neocortex 
in a single coronal macrosection. Aggregates visualised by LFB/haematoxylin histology were rich in CD20+ B cells (A). The location 
of the infiltrates in (A) are marked as asterisks (*) on the serial anti-PLP stained section (B) (Case MS217). By grouping the cases 
based on their relative extent of leptomeningeal inflammation (0/+ vs . ++/+++), we constructed schema depicting all neocortical grey 
matter lesions noted per P1 section, per case (n  = 18). Depth of colour (see heatmap representing percent lesion occurrence with 100% 
indicating tissue was demyelinated in every P1 section in that group) illustrates how frequently an area of neocortex was demyelinated 
in meningeal inflammation rated 0/+ and meningeal inflammation rated ++/+++ MS (C). PLP: proteolipid protein. (A) Scale bar = 200 
µm; (B) Scale bar = 1 cm 
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Substantial subpial cortical grey matter demyelination defines a subset of progressive MS 
cases 
Quantitative image analysis of whole coronal macrosections revealed the proportion of demyelinated cortical 
grey matter to be almost twice that of the proportion of demyelinated white matter. In those cases, with the 
greatest cortical pathology, labelled as cortical GML High MS, there was a near four-fold increase in relative 
area of cortical GML compared to WML. These data are in accordance with the work of Carassiti et al.[25] 
and are supportive of an MS post-mortem cohort characterised by a dominant neocortical demyelinating 
pathology[26]. Amongst our samples, we observed instances of hugely divergent grey over white matter 
pathology (for example, Case MS214 WML accounted for 3.2% of total WM, whilst cortical GML area 
was 43.4% of total cortex; Case MS217 WML area was 3.1% and cortical GML was 59.6%). Cortical GML 
pathology was overwhelmingly subpial in location, with an average of 90.9% of total cortical GML being 
characterised as subpial (Type III/IV) in distribution. Such extensive and disproportionate demyelination 
exceeds that previously reported by ourselves and others and highlights the benefit of working with whole 
coronal macrosection preparations[2,12,18] to better understand MS pathology. 
We have previously noted associations between lymphoid-like structure status and clinical disease measures, 
such as age of onset, age at progression and age at death[13,18]. Our cortical GML High and Low MS cases 
had a similar age of onset to that seen in our earlier studies (median age at onset of 27 and 35 years, 
respectively) but this did not represent a significant difference in our relatively small study. No other 
clinical-pathological correlation was noted, which in part reflects the complex and highly variable 
pathology of this disease, whereby synaptic, neuritic and neuronal loss, alongside demyelination and 
gliosis, variable impact on disease outcome. 
Demyelinating pathology at subpial and subependymal territories 
The correlation between the extent of demyelination of the hippocampus and deep grey (including 
the caudate, putamen, pallidum and thalamus) with that of subpial cortical GML suggests, at least in 
part, a shared pathological mechanism of lesion formation and/or expansion between these regions 
lining superficial surfaces of the pia and ventricles. Subpial demyelinating lesions are a pathological 
hallmark of MS[27] and clinical imaging shows that the thalamus of children with MS, a structure which 
is severely affected in progressive MS[28], displays a specific imaging abnormality as a surface-in gradient 
pattern from the ventricular margin[29]. Adult MS patients also display a gradient of magnetisation 
transfer ratio signal change from the superficial surfaces of the brain: a gradient of signal change, 
declining with distance across the white matter[30,31] when measured from the ventricular surface, and 
across the neocortex from the pial surface, which are most altered in progressive MS[32,33]. A magnetic 
resonance imaging (MRI) signature of gadolinium leptomeningeal enhancement, which may partly 
reflect inflammation of meninges[34], relates to the number and volume of cortical and thalamic 
lesions[35]. These imaging studies support the concepts of meningeal inflammation and outside-in 
CSF factor(s) in lesion genesis. Numerous post-mortem studies have demonstrated a topographical 
association between the extent of immune cell infiltration of the leptomeninges with cortical GM 
demyelination[13,23,36-40], which is also true for subpial tissue of the cerebellar cortex and spinal cord[41-44]. 
This subpial demyelinating pathology of the neocortex is associated with microglia activation, a gradient of 
tissue injury and disruption of the pial glial limiting membrane[16,45]. Therefore, the pattern of neocortical 
lesion location and deep GM pathology is suggestive, at least in part, of an effect of soluble cytotoxic 
mediators from the overlying CSF-filled spaces that contributes to the underlying disease process. 
Soluble mediators of subpial lesions 
Recently, we have demonstrated the overexpression of RNA transcripts associated with pleiotropic 
chemokines and cytokines in the isolated meningeal tissue from cases characterised by extensive 
leptomeningeal inflammation and subpial demyelination[46,47]. The profile of elevated mediators, many 
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of which are associated with processes of lymphoid neogenesis, were mirrored by the finding of elevated 
protein levels of many of the same factors in the matched post-mortem CSF, which were also differentially 
expressed in an independent cohort of newly diagnosed MS patients with a clinical and radiological 
signature of substantial cortical pathology[47]. TNF and IFNγ are amongst those differentially expressed in 
patients with a cortical phenotype and these cytokines mediate a rapid pattern of cortical demyelination 
and microglia/macrophage activation when injected into the subarachnoid space of animals with 
subclinical autoimmune encephalitis[46]. These findings imply that lymphoid follicle-like structures, and 
infiltrates outside of these semi-organised structures, are a source of damaging factors that drive subpial 
pathology. Sampling CSF may reveal disease-relevant biomarkers of activity to aid therapeutic decision 
making[48]. 
Subpial cortical GMLs are associated with the loss of neurons of the superficial cortical layers, an elevated 
number of complement activated neurons and glia, together with substantial neuritic and synaptic 
loss[13,16,45,49-53]. The most striking pathological changes are found in the superficial cortical laminae, 
with a gradient of lessening neuronal damage with distance from the pia[16]. Neurons and glia of the 
MS cortex are exposed to elevated excitotoxins and reactive free radicals[54,55], are energy depleted and 
display mitochondrial pathology, which may contribute to further neurodegeneration[56-58]. There is an 
imbalance between TNF receptor 1/2 anti-apoptotic pathways vs. pro-death signals in the progressive MS 
cortex and oligodendrocytes are vulnerable to degenerate by a TNF receptor type 1/Receptor-interacting 
protein kinase type 1 necroptotic cascade[59,60]. Immunoglobulins derived from meningeal plasma cells 
are enriched in the MS neocortex, and products of central CD20+ B effector cells are directly toxic to 
cultured neurons and oligodendrocytes[61-63]. Alongside myriad immune mediators, MS CSF is enriched in 
bio-active lipids, whose levels associate with disease severity[64-66]. Lipid sterols, including key products of 
cholesterol metabolism and ceramide, can be directly neurotoxic. For example, C16:0 and C24:0 ceramides 
are enriched in MS patient CSF and can mediate neuroaxonal pathology and mitochondrial dysfunction[65], 
whilst simvastatin, a cholesterol-reducing therapy that enters the CNS, is associated with a slowing of brain 
atrophy in SPMS[67]. We currently have identified neither the combination of damaging factors that are 
causative of injury nor the relationship between these mediators with clinical progression on an individual 
level.
Lesions of the deeper cortical laminae (leukocortical or Type I cortical GMLs) are centred on cortical 
veins, typically contain greater numbers of activated microglia/macrophages than subpial lesions[53], and 
their relative area correlated with the extent of white matter lesion area in the same case. The statistical 
association between cortical and subcortical lesions, both characterised by an inflamed central vein, 
suggests they both share similar a mechanism of formation, which is in part different to lesions of the 
superficial grey matter structures. MRI is adept at resolving leukocortical GMLs, whilst even ultra-high 
field MRI detects only a fraction of all subpial lesions[68]. Our finding of an association between the relative 
area of leukocortical GML and WML area may explain the correlation between white matter and cortical 
grey matter lesions reported by MRI. 
Methodological considerations and study limitations 
The analysis of whole coronal macrosections allows the study of cortical lesions in continuity, improves the 
accuracy of their interpretation and the relationship with other pathological features, such as meningeal 
inflammation or lesions in different anatomical sites[19,69,70]. The handling of such large tissue samples is 
not trivial and this restricted the n number for our work, which may have meant our clinical-pathological 
comparisons were statistically underpowered [for instance, to observe a significant difference in age 
of onset between our GML High and Low MS cases, post-hoc power calculations (b = 0.8) predicted 
a cohort of at least 40 cases would be required (a = 0.05)]. Whole brain immersion fixation often led 
to some deformation of tissues, such that it was not always possible to align anatomical structures of 
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interest, meaning that we could not, for example, report lesion measures for separate deep GM structures. 
Nevertheless, the use of whole coronal sections reduces observer variation between individual cases, 
increases the accuracy of observations, and ensures comparisons between different forebrain areas, which 
are invaluable for the study of this heterogeneous disease.
In conclusion, our quantitative histological analysis revealed global grey matter demyelination and 
meningeal inflammation to be substantial in a subset of progressive MS brains. Cases defined by a 
substantial cortical GML load displayed greater microglia/macrophage activation, larger areas of deep 
grey matter pathology but little change in white matter lesion area, which highlights the partially separate 
pathogenetic mechanisms of lesion evolution (or susceptibility to damage) in these compartments. The 
distribution of subcortical and deep GML in MS is consistent with the presence of soluble proinflammatory 
factors in the subarachnoid space and ventricular CSF and furthers the need to identify companion 
biomarkers of cortical pathology to aid patient monitoring and therapeutic choice.
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